Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kura Oncology (KURA) Interest & Investment Income (2023 - 2026)

Kura Oncology has reported Interest & Investment Income over the past 4 years, most recently at $5.8 million for Q1 2026.

  • Quarterly Interest & Investment Income fell 26.06% to $5.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $25.3 million through Mar 2026, down 0.58% year-over-year, with the annual reading at $26.8 million for FY2025, 17.18% up from the prior year.
  • Interest & Investment Income was $5.8 million for Q1 2026 at Kura Oncology, down from $7.9 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $7.9 million in Q1 2025 and troughed at $2.9 million in Q1 2023.
  • The 4-year median for Interest & Investment Income is $5.5 million (2024), against an average of $5.1 million.
  • Year-over-year, Interest & Investment Income soared 86.12% in 2024 and then decreased 26.06% in 2026.
  • A 4-year view of Interest & Investment Income shows it stood at $4.4 million in 2023, then rose by 29.5% to $5.7 million in 2024, then surged by 39.23% to $7.9 million in 2025, then decreased by 26.06% to $5.8 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Interest & Investment Income are $5.8 million (Q1 2026), $7.9 million (Q1 2025), and $5.7 million (Q4 2024).